It has been seen that if a person gets infected by COVID 19 the disease makes the patient go in a hyper-coagulable state.
This increases the risk of clot formation in bed ridden patients if they stay for large time bed ridden or are at a high risk for coagulation like in Pregnancy.
The clot formation in patients may lead to several problems such as-
3.Disseminated Intravascular Coagulation
The hyper-coagulable state might be very dangerous hence needs to be continuously monitored using estimation of D-Dimer levels.
-According to a study
Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia
“Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020 Jun;18(6):1421-1424. doi: 10.1111/jth.14830. Epub 2020 May 6. PMID: 32271988; PMCID: PMC7262324.”
The incidence of VTE in patients with severe NCP is 25% (20/81), which may be related to poor prognosis. The significant increase of D-dimer in severe Novel Corona Virus patients is a good index for identifying high-risk groups of Venous Thromboembolism.
-According to one more study done for COVID related risk of Stroke and associated Neurological Symptoms done by
Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Transl Stroke Res. 2020 Jun;11(3):322-325. doi: 10.1007/s12975-020-00818-9. Epub 2020 May 7. PMID: 32378030; PMCID: PMC7202903.
The COVID-19 pandemic is associated with neurological symptoms and complications including stroke. There is hyper coagulability associated with COVID-19 that is likely a “sepsis-induced coagulopathy” and may predispose to stroke. The SARS-CoV-2 virus binds to angiotensin-converting enzyme 2 (ACE2) present on brain endothelial and smooth muscle cells. ACE2 is a key part of the renin angiotensin system (RAS) and a counterbalance to angiotensin-converting enzyme 1 (ACE1) and angiotensin II. Angiotensin II is pro-inflammatory, is vasoconstrictive, and promotes organ damage. Depletion of ACE2 by SARS-CoV-2 may tip the balance in favour of the “harmful” ACE1/angiotensin II axis and promote tissue injury including stroke. There is a rationale to continue to treat with tissue plasminogen activator for COVID-19-related stroke and low molecular weight heparinoids may reduce thrombosis and mortality in sepsis-induced coagulopathy.
This article has been studied and reveiwed by Dr.Udbhav and has been written for information purposes. This does not reflect the official position of Neurological Disoreders website .
This article has information updated till 29th Dec 2020 and any further information will be updated soon.